Kamada Pharmaceuticals - Company Profile
Powered by
All the data and insights you need on Kamada Pharmaceuticals in one report.
$295
- Save hours of research time and resources with
our up-to-date Kamada Pharmaceuticals Strategy Report
- Understand Kamada Pharmaceuticals position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Kamada Pharmaceuticals patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
DK3723790T3 | Application | Fremgangsmåder til inducering af immuntolerance og reduktion af anti-lægemiddel-antistofrespons | A61K2039/54; A61K2039/545; A61K2039/577; A61K38/57; A61K39/001; A61K9/0019; A61K9/0078; A61P37/02 | April 22, 2024 |
FI3723790T3 | Grant | Methods of inducing immune tolerance and reducing anti-drug antibody response | A61K2039/54; A61K2039/545; A61K2039/577; A61K38/57; A61K39/001; A61K9/0019; A61K9/0078; A61P37/02 | April 19, 2024 |
WO2024075112A1 | Application | Highly fucosylated recombinant human alpha 1 antitrypsin (AAT) protein having immunomodulatory activity and compositions comprising the same | A61P11/06; C12N15/00; A61K38/55; C12P21/00; A61P11/00; C07K14/81 | April 11, 2024 |
EP3723790B1 | Grant | Verfahren zur induzierung der immuntoleranz und zur verminderung der antiinflammatorischen antikörperreaktion | A61K2039/54; A61K2039/545; A61K2039/577; A61K38/57; A61K39/001; A61K9/0019; A61K9/0078; A61P37/02 | March 13, 2024 |
IL275328B2 | Grant | Methods of inducing immune tolerance and reducing anti-drug antibody response | A61K2039/54; A61K2039/545; A61K2039/577; A61K38/57; A61K39/001; A61K9/0019; A61K9/0078; A61P37/02 | March 01, 2024 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer